InSilicoTrials generates digital regulatory-grade evidence using FDA-supported in silico methodologies. Simulation, predictive intelligence, and AI can be applied to the whole drug development lifecycle—from discovery and clinical trials to commercial strategies. Our platform supports diverse disease areas with cutting-edge models, synthetic patient simulations, and virtual patients, while significantly cutting R&D time and costs. Our technology is used by both biotechs and venture capital firms to de-risk investments and promote licensing opportunities.